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Purpose: Fluoroquinolones, rapidly gaining prominence in treatment of Stenotroph-
omonas maltophilia (SMP), are noted for their potency and tolerability. However, 
SMP may rapidly acquire resistance to fluoroquinolones. We evaluated associations 
of clinical factors with acquisition of levofloxacin resistance (LFr) in SMP. Materi-
als and Methods: Our retrospective cohort study was based on patient data collect-
ed between January 2008 and June 2010. Through screening of 1275 patients, we 
identified 122 patients with data for SMP antibiotic susceptibility testing in ≥3 serial 
SMP isolates. Results: We assigned the 122 patients to either the SS group (n=54) in 
which levofloxacin susceptibility was maintained or the SR group (n=31) in which 
susceptible SMP acquired resistance. In multivariate regression analysis, exposure to 
levofloxacin for more than 3 weeks [odds ratio (OR) 15.39, 95% confidential inter-
val (CI) 3.08--76.93, p=0.001] and co-infection or co-colonization with Klebsiella 
pneumoniae resistant to levofloxacin (OR 4.85, 95% CI 1.16--20.24, p=0.030) were 
independently associated with LFr acquisition in SMP. Conclusion: Acquisition of 
LFr during serial sampling of SMP was related to the levofloxacin exposure.
Key Words:   Stenotrophomonas maltophilia, fluoroquinolones, levofloxacin, drug 
resistance
INTRODUCTION
Stenotrophomonas maltophilia (S. maltophilia) is an emergent pathogen in health-
care facilities worldwide, causing mainly pneumonia or septicemia related or unre-
lated to catheter use. Patients with immunodeficiency are especially at risk.1-3 Serious 
infection attributed to S. maltophilia is a significant cause of mortality in patients 
with hematologic malignancies,4 with mortality rates up to 37.5%.5
S. maltophilia is intrinsically resistant to antibiotics that could be excluded by 
multidrug efflux pumps and/or inactivated by β-lactamase and aminoglycoside-
modifying enzymes.6 Trimethoprim-sulfamethoxazole (TMP-SMX), historically 
the first line of defense in S. maltophilia infection,7 may induce resistance related 
to class 1 integrons containing the sul1 sulfonamide resistance gene and insertion 
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We screened the data for 3029 S. maltophilia isolates 
from 1275 patients, and identified 528 isolates with data for 
serial isolation and all AST results from 122 patients (Fig. 
1). We stratified these 122 patients into either the SS group 
(n=54) whose records showed maintenance of levofloxacin 
susceptibility from the first S. maltophilia isolate to the last 
isolate recorded or the SR group (n=31) with data confirm-
ing transition from levofloxacin susceptibility to resistance 
in serial S. maltophilia isolates. However, we excluded an 
RR group (85 isolates from 21 patients) whose records re-
vealed the maintenance of levofloxacin resistance from the 
first S. maltophilia isolate to the last isolate recorded from 
our study analysis. Additionally, patients (12 isolates from 4 
patients) with data confirming transition from levofloxacin 
resistance to susceptibility and patients (86 isolates from 12 
patients) with inconstant AST results for levofloxacin were 
excluded from the analysis (Fig. 1).
In vitro antimicrobial susceptibility testing
All bacterial species were identified using conventional 
methods and/or the ATB 32GN system (bioMerieux, Marcy 
l’Etoile, France). Antimicrobial susceptibility was tested by 
the Clinical and Laboratory Standards Institute (CLSI) agar 
dilution method.18 The antimicrobial agents used for AST 
were TMP-SMX (Dong Wha Pharmaceutical Co. Ltd., 
Seoul, Korea); levofloxacin (Daiichi Sankyo Co. Ltd., To-
kyo, Japan); minocycline (SK Chemicals Co. Ltd., Life 
Sciences, Seoul, Korea); ceftazidime, amikacin, and genta-
micin (Sigma Chemical Co., St. Louis, MO, USA); tigecy-
cline (Wyeth Research, Pearl River, NY, USA); imipenem 
(Choongwae Pharma Corp., Seoul, Korea); and piperacil-
lin/tazobactam (Yuhan Co. Ltd., Seoul, Korea). 
Definitions
The index isolate was defined as the last levofloxacin-sus-
ceptible isolate cultured from a patient in the SS group and 
element common region elements containing the sul2 resis-
tance gene.6,8,9 However, rates reported for resistance to 
TMP-SMX in S. maltophilia are generally less than 10%.10-12
Clinically, the use of TMP-SMX in S. maltophilia infec-
tion is limited by adverse effects of the drug, including skin 
eruptions, hepato- and renal toxicity, and bone marrow sup-
pression.7,13 Additionally, resistance to TMP-SMX in S. 
maltophilia is increasing at certain centers.8,13
Fluoroquinolones, including levofloxacin and moxifloxa-
cin, are an attractive alternative for treating S. maltophilia 
infection, because they are well-tolerated and effective, 
compared to TMP-SMX, and because of their low rates of 
microbial resistance.7,11,13-16 However, S. maltophilia can 
rapidly acquire resistance to fluoroquinolones, especially in 
monotherapy, and this may limit their use in combination 
therapy.17 In this study, we investigated the poorly under-
stood relationships between clinical factors and the acquisi-
tion of levofloxacin resistance in S. maltophilia. 
MATERIALS AND METHODS
　　　
Subjects and study design
This retrospective cohort study was conducted at Severance 
Hospital, a 2000-bed university-affiliated teaching hospital 
and tertiary care referral center in Seoul, South Korea, based 
on data collected from January 2008 to June 2010. Patients 
who met all of the following conditions were eligible for 
this study: 1) age 18 years old or older; 2) ≥3 serial isola-
tions of S. maltophilia by culture, accompanied by in vitro 
antimicrobial susceptibility testing (AST) in any clinical 
specimen; and 3) results for three or more consecutive ASTs 
of S. maltophilia for levofloxacin in clinical specimens from 
the same system (e.g., the respiratory, urinary or biliary tract, 
peritoneal or pleural fluid, or an external wound) at intervals 
from 3 days to 3 months. 
Fig. 1. Selection of S. maltophilia isolates and patients. SMP, Stenotrophomonas maltophilia; AST, antimicrobial susceptibility test; S, susceptible; R, resistant.
Definition of serial isolates
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Total isolates of SMP
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R→S
12 isolates from 4 patients
528 isolates from 122 patients
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1648 isolates not serial
3029 isolates from 1275 patients
853 isolates without AST
R→R
85 isolates from 21 patients
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Inconstant
86 isolates from 12 patients
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continuous variables had normal distribution, these were ex-
pressed as mean±standard deviation. Continuous variables 
without normal distribution were expressed as median (inter-
quartile range). We used Student’s t-test or Mann-Whitney U 
test and the χ2 test or Fisher’s exact test to compare continu-
ous and categorical variables, respectively, in a univariate 
analysis of clinical characteristics in the SR and SS groups. 
Variables with p-values less than 0.10 in univariate analysis 
were included in a multivariate logistic regression analysis to 
identify clinical factors associated with acquisition of levo-
floxacin resistance in S. maltophilia. Results from the multi-
variate analysis are expressed as an odds ratio (OR) and 95% 
confidence intervals (CIs). A two-tailed p-value <0.05 was 
taken to indicate significance. All statistical analyses were 
performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
 
RESULTS
 
The SS and SR groups were similar in age and gender (Table 
1). A significantly higher proportion of patients in the SR 
group than in the SS group were in ARF requiring RRT 
as the first levofloxacin-resistant isolate from one patient in 
the SR group.
Data collection
The clinical data at the time of identification of the index 
isolate were collected through review of electronic medical 
records. Coexisting conditions of interest included length of 
hospital stay, intensive care unit admission, use of mechani-
cal ventilation, current tracheostomy status, acute renal fail-
ure (ARF) with renal replacement therapy (RRT), neutrope-
nia, and steroid or immunosuppressant use, as well as the 
Charlson’s comorbidity index score. We recorded the histo-
ry and total duration of all systemic antibiotic exposures 
within 3 months from identification of the index isolate. To 
evaluate the effect of co-infection or co-colonization with 
other bacteria on the acquisition of resistance to levofloxa-
cin in S. maltophilia, the data for co-infection or co-coloni-
zation were evaluated in parallel with results of AST for 
fluoroquinolones.
Statistical analysis
Categorical data are expressed as a number (percent). If the 
Table 1. Clinical Characteristics of the Study Population and Subgroups SS, Defined as the Maintenance of Levofloxacin Sus-
ceptibility, and SR, Defined as a Change from Levofloxacin Susceptibility to Resistance
Characteristics Total (n=85) SS group (n=54) SR group (n=31) p value
Age, yrs 62.7±14.4 61.5±14.4 64.8±14.4  0.314* 
Gender, male    61 (71.8)    37 (68.5)    24 (77.4) 0.380†
Clinical specimen, yes
    Respiratory tract    56 (65.9)    35 (64.8)    21 (67.7) 
    Biliary tract    10 (11.8)      7 (13.0)      3 (9.7) 
    External wound      8 (9.4)      6 (11.1)      2 (6.5) 
    Intraperitoneal space      7 (8.2)      4 (7.4)      3 (9.7) 
    Urinary tract      3 (3.5)      1 (1.9)      2 (6.5) 
    Pleural space      1 (1.2)      1 (1.9)      0 (0.0) 
Hospital stay, days 65.0 (37.5--93.5) 62.5 (35.5--81.2) 76.0 (38.0--121.0) 0.267‡ 
ICU admission, yes     60 (70.6)    36 (66.7)    24 (77.4) 0.295†
Mechanical ventilation, yes     53 (62.4)    31 (57.4)    22 (71.0) 0.214†
Tracheostomy, yes     46 (54.1)    30 (55.6)    16 (51.6) 0.725†
ARF on RRT, yes     12 (14.1)      4 (7.4)      8 (25.8) 0.026§
Neutropenia, yes       4 (4.7)      2 (3.7)      2 (6.5) 0.620§
Corticosteroid use, yes     31 (36.5)    17 (31.5)    14 (45.2) 0.207†
Immunosuppressant use, yes      4 (4.7)      2 (3.7)      2 (6.5) 0.620§
Charlson’s comorbidity index      3 (2--5)      3 (2--6)      3 (2--5) 0.417‡
ICU, intensive care unit; ARF, acute renal failure; RRT, renal replacement therapy.
Data are expressed as the mean±SD or number (percent) or median (interquartile range). 
*Student’s t-test. 
†χ2-test. 
‡Mann-Whitney U test. 
§Fisher’s exact test. 
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fluoroquinolones through various mechanisms, including 1) 
efflux pump systems, such as SmeABC and SmeDEF,19,20 or 
2) mutations in outer-membrane porin proteins.21 A previous 
study suggested that spontaneous mutations conferring re-
sistance to fluoroquinolones occur at frequencies between 
10-5 to 10-752 after quinolones therapy in S. maltophilia.22 In a 
clinical study at the MD. Anderson Cancer Center, use of 
fluoroquinolones in the previous 90 days was independently 
associated with emergence of multidrug resistant S. malto-
philia infection in cancer patients.23 In a case-control study, 
Spanik, et al.24 found a positive association of prophylactic 
fluoroquinolones use with bacteremia by MDR gram-nega-
tive bacilli including S. maltophilia in neutropenic cancer 
patients. Thus experimental and clinical data from multiple 
studies, including this one, associate fluoroquinolones ex-
posure with acquired resistance to fluoroquinolones in S. 
maltophilia.
Co-infection or co-colonization with levofloxacin-resis-
tant K. pneumoniae presented another independent clinical 
factor in acquisition of levofloxacin resistance in S. malto-
philia. Co-infection and co-colonization with other bacterial 
species, especially those with resistance to fluoroquinolones, 
are clinically relevant because the species may actively ex-
change drug resistance genes by means of plasmids and 
transposons.25 Clinical co-infection of S. maltophilia with 
other pathogens (e.g., other glucose-non-fermenting gram-
negative bacteria including Pseudomonas aeruginosa, Burk-
holderia species and Acinetobacter baumannii; Enterobac-
teriaceae including Escherichia coli, Klebsiella species and 
Enterobacter species; Staphylococcus aureus including 
methicillin-resistant S. aureus; Enterococcus species; Bacte-
roides species; and Candida albicans) is confirmed through 
(25.8% vs. 7.4%, p=0.026). Other coexisting conditions did 
not differ significantly between the two groups (Table 1). 
The total duration of exposure to levofloxacin within 3 
months from identification of the index isolate was signifi-
cantly longer in the SR group [33 (9--42) days] than the SS 
group [11 (4--64) days, p=0.044] (Table 2). However, the 
total duration of exposure to anti-pseudomonal penicillins, 
3rd cephalosporins, 4th cephalosporins, ciprofloxacin, car-
bapenems, aminoglycosides, glycopeptides, and metronida-
zole did not show significant differences between the SS 
and SR groups (Table 2). Co-infection or co-colonization 
with ciprofloxacin-resistant Staphylococcus aureus was sig-
nificantly more common in the SS group than in the SR 
group (31.5% vs. 9.7%, p=0.032). The SR group had sig-
nificantly higher percentages of co-infection or co-coloni-
zation with any gram-negative bacteria and with Klebsiella 
pneumonia resistant to levofloxacin (58.1% vs. 35.2%, p= 
0.041; 32.3% vs. 9.3%, p=0.007, respectively) (Table 3).
In the final multivariate logistic regression analysis, expo-
sure to levofloxacin for more than 3 weeks (OR 15.39, 95% 
CI 3.08--76.93, p=0.001) and co-infection or co-colonization 
with K. pneumoniae resistant to levofloxacin (OR 4.85, 95% 
CI 1.16--20.24, p=0.030) were clinical factors independent-
ly associated with the acquisition of resistance to levofloxa-
cin in S. maltophilia (Table 4). 
DISCUSSION
This study confirmed the acquisition of levofloxacin resis-
tance in S. maltophilia during clinical application of the 
drug. S. maltophilia may potentially develop resistance to 
Table 2. Total Duration of Systemic Antibiotic Exposure within 3 Months from Identification of the Index Isolate in Patient 
Groups SS Was Defined as the Maintenance of Levofloxacin Susceptibility and SR Was Defined as a Change from Levo-
floxacin Susceptibility to Resistance
Antibiotics, total exposed  
  duration, days
Total (n=85) SS group (n=54) SR group (n=31) p value*
Anti-pseudomonal penicillins 22 (10--33) 24 (7--35) 21 (11--31) 0.911
3rd cephalosporins 28 (12--63) 44 (19--71) 28 (11--49) 0.110
4th cephalosporins 18 (9--35) 18 (3--45) 18 (10--29) 1.000
Ciprofloxacin 20 (11--31) 19 (8--33) 20 (14--30) 0.564
Levofloxacin 24 (7--46) 11 (4--64) 33 (9--42) 0.044
Carbapenems 12 (3--31) 17 (1--43) 12 (3--30) 0.736
Aminoglycosides 26 (13--49) 26 (14--80) 25 (12--43) 0.193 
Glycopeptides 14 (6--36) 23 (8--46) 12 (5--31) 0.149
Metronidazole 25 (11--49) 21 (7--38) 30 (3--48) 0.440
Data are expressed as the median (interquartile range). 
*Mann-Whitney U test. 
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Table 3. Characteristics of Co-Infecting and Co-Colonizing Microorganisms in Patient Subgroups SS, Defined as the Mainte-
nance of Levofloxacin Susceptibility, and SR, Defined as a Change from Levofloxacin Susceptibility to Resistance
Microorganisms and their 
  sensitivity to selected antibiotics
Total (n=85) SS group (n=54) SR group (n=31) p value
Any Gram-positive 46 (54.1) 31 (57.4) 15 (48.4) 0.422*
    Ciprofloxacin (R) 35 (41.2) 25 (46.3) 10 (32.3) 0.206*
Staphylococcus aureus 24 (28.2) 19 (35.2)   5 (16.1) 0.060†
    Ciprofloxacin (R) 20 (23.5) 17 (31.5)   3 (9.7) 0.032†
Coagulase-negative staphylococci 18 (21.2) 13 (24.1)   5 (16.1) 0.388†
    Ciprofloxacin (R)   7 (8.2)   6 (11.1)   1 (3.2) 0.414†
Enterococcus sp. 21 (24.7) 12 (22.2)   9 (29.0) 0.483*
    Ciprofloxacin (R) 17 (20.0)   9 (16.7)   8 (25.8) 0.311*
    Norfloxacin (R)   7 (8.2)   4 (7.4)   3 (9.7) 0.702†
    Any FQ (R) 18 (21.2) 10 (18.5)   8 (25.8) 0.429*
Any gram-negative 64 (75.3) 41 (75.9) 23 (74.2) 0.859*
    Ciprofloxacin (R) 29 (34.1) 18 (33.3) 11 (35.5) 0.840*
    Levofloxacin (R) 37 (43.5) 19 (35.2) 18 (58.1) 0.041*
    Any FQ (R) 44 (51.8) 25 (46.3) 19 (61.3) 0.183*
Acinetobacter baumannii 28 (32.9) 20 (37.0)   8 (25.8) 0.289*
    Ciprofloxacin (R)   7 (8.2)   5 (9.3)   2 (6.5) 1.000†
    Levofloxacin (R) 16 (18.8)   9 (16.7)   7 (22.6) 0.502*
    Any FQ (R) 20 (23.5) 13 (24.1)   7 (22.6) 0.876*
Pseudomonas aeruginosa 36 (42.4) 23 (42.6) 13 (41.9) 0.953*
    Ciprofloxacin (R) 24 (28.2) 13 (24.1) 11 (35.5) 0.261*
    Levofloxacin (R)   7 (8.2)   2 (3.7)   5 (16.1) 0.094†
    Any FQ (R) 24 (28.2) 13 (24.1) 11 (35.5) 0.261*
Klebsiella pneumoniae 21 (24.7)   9 (16.7) 12 (38.7) 0.023*
    Levofloxacin (R) 15 (17.6)   5 (9.3) 10 (32.3) 0.007†
Escherichia coli   9 (10.6)   7 (13.0)   2 (6.5) 0.476†
    Levofloxacin (R)   5 (5.9)   4 (7.4)   1 (3.2) 0.648†
Enterobacter spp. 16 (18.8) 12 (22.2)   4 (12.9) 0.392†
    Levofloxacin (R)   6 (7.1)   4 (7.4)   2 (6.5) 1.000†
Serratia marcescens 10 (11.8)   6 (11.1)   4 (12.9) 1.000†
    Levofloxacin (R)   4 (4.7)   2 (3.7)   2 (6.5) 0.620†
 Other gram-negatives 21 (24.7) 14 (25.9)   7 (22.6) 0.731*
    Ciprofloxacin (R)   1 (1.2)   0 (0.0)   1 (3.2) 0.365†
    Levofloxacin (R)   4 (4.7)   1 (1.9)   3 (9.7) 0.135†
    Any FQ (R)   4 (4.7)   1 (1.9)   3 (9.7) 0.135†
FQ, fluoroquinolones; R, resistant.
Data are expressed as the number (percent). 
*χ2-test.  
†Fisher’s exact test. 
Table 4. Multivariate Logistic Regression Analysis of Factors Related to Acquisition of Levofloxacin Resistance in S. maltophilia
Variables OR 95% CI p value 
ARF on RRT   3.95   0.66--23.65 0.132 
Co-infection/co-colonization
    S. aureus, ciprofloxacin (R)   0.26 0.06--1.24 0.091 
    K. pneumoniae, levofloxacin (R)   4.85   1.16--20.24 0.030 
    P. aeruginosa, levofloxacin (R)   1.36 0.37--2.49 0.475
Total exposed duration to levofloxacin, ≥3 wks 15.39   3.08--76.93 0.001 
OR, odds ratio; CI, confidential interval; ARF, acute renal failure; RRT, renal replacement therapy; R, resistant.
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